Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CYCLOSPORINE

All products: not a benefit

Teva-Cyclosporine · DIN 02462486 · 0.05% w/v · Oph Emuls-0.4mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Cyclosporine · DIN 02462486 Manufacturer: Teva Canada Limited; listing date 2018-01-31 Health Canada: Marketed since 2017-12-04 · brand TEVA-CYCLOSPORINE · ATC S01XA18 CICLOSPORIN · form Emulsion · route Ophthalmic · ingredients CYCLOSPORINE 0.05 %/W/V · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95023 · Verify on the e-Formulary ↗ (DIN 02462486)

Source record
DIN 02462486: Teva-Cyclosporine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 520892001; group id 602; item number 1562; lccId None; manufacturer id TEV Source form: Oph Emuls-0.4mL Pk; strength: 0.05% w/v Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $4.1658; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02462486 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95023
Interchangeable products
Restasis · DIN 02355655 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (52:08:92 Anti-Inflammatory Agents, Miscellaneous) and how they are covered
No products matched this class search: “52:08:92”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 52:04:04 Antibiotics, 52:04:12 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: active rheumatoid arthritis, psoriasis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ACITRETIN, LEFLUNOMIDE, PENICILLAMINE ACITRETIN · General benefit 1 INDICATIONS SORIATANE (acitretin) is indicated for: • Severe psoriasis (includes erythrodermic and pustular types) • Other disorders of keratinization Severe psoriasis is a condition that involves more than 10% of body surface area or is physically, occupationally or psychologically disabling. PM: https://pdf.hres.ca/dpd_pm/00080165.PDF; date APR 04, 2025; DIN 02070847; fetched 2026-09-10 Product monograph APREMILAST · Off-Formulary Interchangeable, not an ODB benefit Indications • Plaque Psoriasis OTEZLA (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. PM: https://pdf.hres.ca/dpd_pm/00084256.PDF; date 2026-04-10; DIN 02434318; fetched 2026-09-10 Product monograph BIMEKIZUMAB · Limited Use, codes 641 Indications Bimzelx (bimekizumab injection) is indicated for: • Psoriasis (PsO) The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10 Product monograph • Psoriasis (PsO) The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10 Product monograph ETANERCEPT · Limited Use, codes 512, 513, 514, 563, 591 (3), Limited Use, codes 498, 499, 514, 563, 591 (4) • treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00083562.PDF; date August 31, 2016; DIN 02455323; fetched 2026-09-10 Product monograph INFLIXIMAB · Limited Use, codes 468, 469, 470, 471, 477, 478, 479 (2), Limited Use, codes 541, 542, 543, 544, 545, 546, 547 (1), Limited Use, codes 715, 716, 718 (2), Limited Use, codes 592, 593, 594, 595, 596, 597, 598 (1) • treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy. For patients with chronic moderate plaque psoriasis, RemdantryTM should be used after phototherapy has been shown to be ineffective or inappropriate. When assessing the severity of psoriasis, the health professional should consider the extent of involvement, location of lesions, response to previous treatments, and impact of disease on the patient’s PM: https://pdf.hres.ca/dpd_pm/00081840.PDF; date September 2, 2025; DIN 02419475; fetched 2026-09-10 Product monograph LEFLUNOMIDE · General benefit ARAVA is indicated in adults for the treatment of active rheumatoid arthritis. 1.1 Pediatrics The use in patients less than 18 years of age is contraindicated. 1.2 Geriatrics No dosage adjustment is needed in patients over 65 years of age. PM: https://pdf.hres.ca/dpd_pm/00083555.PDF; date not captured; DIN 02241888; fetched 2026-09-10 Product monograph METHOTREXATE · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) • Severe disabling psoriasis/psoriatic arthritis PM: https://pdf.hres.ca/dpd_pm/00078227.PDF; date JAN 08, 2025; DIN 02170698; fetched 2026-09-10 Product monograph PENICILLAMINE · General benefit INDICATIONS AND CLINICAL USE CUPRIMINE (penicillamine capsules, USP) is indicated for:  treatment of Wilson's disease  chronic lead poisoning  cystinuria, and  In patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. PM: https://pdf.hres.ca/dpd_pm/00054287.PDF; date not captured; DIN 00016055; fetched 2026-09-10 Product monograph RISANKIZUMAB · Limited Use, codes 574 Indications SKYRIZI (risankizumab injection) is indicated for: • the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00085642.PDF; date 2026-07-08; DIN 02519283; fetched 2026-09-10 Product monograph SECUKINUMAB · Limited Use, codes 476 Indications COSENTYX® (secukinumab injection/secukinumab for injection) is indicated for: Adult patients Plaque psoriasis COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10 Product monograph Hidradenitis Suppurativa COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy (see 14.1.5 Hidradenitis suppurativa). 1.1 Pediatrics Plaque psoriasis COSENTYX (secukinumab injection/secukinumab for injection) is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 year and older who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10 Product monograph and 3 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications Solid Organ Transplantation NEORAL® capsules and oral solution and SANDIMMUNE I.V.® (cyclosporine) are indicated in the prevention of graft rejection following solid organ transplantation and in the treatment of transplant rejection in patients previously receiving other immunosuppressive agents. Bone Marrow Transplantation NEORAL capsules and oral solution and SANDIMMUNE I.V. (cyclosporine) are indicated in the prevention of graft rejection following bone marrow transplantation and the prevention or treatment of graft- versus-host disease (GVHD). Psoriasis NEORAL capsules and oral solution (cyclosporine) are indicated for the treatment of severe psoriasis in patients for whom conventional therapy is ineffective or inappropriate. Rheumatoid Arthritis NEORAL capsules and oral solution (cyclosporine) are also indicated for the treatment of severe active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents are inappropriate or ineffective. Nephrotic Syndrome NEORAL capsules and oral solution (cyclosporine) are indicated in adults and children for steroid dependent and steroid resistant nephrotic syndrome due to glomerular dise… https://pdf.hres.ca/dpd_pm/00085584.PDF PM date: 2026-07-30 Source product: NEORAL; DIN 02150662; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Teva-Cyclosporine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026